The estimated Net Worth of William K Heiden is at least $6.11 Million dollars as of 20 May 2024. Mr. Heiden owns over 4,500 units of Atara Biotherapeutics Inc stock worth over $37,395 and over the last 12 years he sold ATRA stock worth over $5,769,203. In addition, he makes $302,492 as Independent Director at Atara Biotherapeutics Inc.
William has made over 12 trades of the Atara Biotherapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 4,500 units of ATRA stock worth $37,395 on 20 May 2024.
The largest trade he's ever made was buying 100,000 units of Atara Biotherapeutics Inc stock on 10 November 2023 worth over $25,000. On average, William trades about 4,987 units every 82 days since 2012. As of 20 May 2024 he still owns at least 4,500 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Mr. Heiden stock trades at the bottom of the page.
William K. Heiden serves as Independent Director of the Company since November 2015. Mr. Heiden has served as the President and Chief Executive Officer, and as a member of the board of directors, of AMAG Pharmaceuticals, Inc., a pharmaceutical company, since May 2012. Prior to joining AMAG Pharmaceuticals, Mr. Heiden served as President and Chief Executive Officer of GTC Biotherapeutics, Inc. (now known as rEVO Biologics, Inc.), a biotherapeutics company, starting in June 2010. From September 2004 until December 2008, Mr. Heiden served as President and Chief Executive Officer of Elixir Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Elixir Pharmaceuticals, Mr. Heiden served as President and Chief Operating Officer of Praecis Pharmaceuticals Incorporated (which was acquired by GlaxoSmithKline), from 2002 to 2004. From 1987 to 2002, Mr. Heiden progressed through various positions of increasing responsibility at Schering-Plough Corporation (which was acquired by Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. Mr. Heiden holds an M.B.A. from Cornell University’s Johnson Graduate School of Management, a M.I.M. degree from the University of Louvain and a B.A. degree from the University of Florida.
As the Independent Director of Atara Biotherapeutics Inc, the total compensation of William Heiden at Atara Biotherapeutics Inc is $302,492. There are 11 executives at Atara Biotherapeutics Inc getting paid more, with Pascal Touchon having the highest compensation of $6,637,310.
William Heiden is 60, he's been the Independent Director of Atara Biotherapeutics Inc since 2015. There are 2 older and 15 younger executives at Atara Biotherapeutics Inc. The oldest executive at Atara Biotherapeutics Inc is Roy Baynes, 65, who is the Independent Director.
William's mailing address filed with the SEC is 9704 MEDICAL CENTER DRIVE, , ROCKVILLE, MD, 20850.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier, and Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: